Lakefront Biotherapeutics (LKFT) Cost of Revenue (2021 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cost of Revenue for 6 consecutive years, with $5.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cost of Revenue fell 61.09% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $24.2 million (down 29.93% YoY), while the FY2025 annual figure was $34.6 million, down 7.09% from the prior year.
• Cost of Revenue advanced to $5.6 million in Q1 2026 per LKFT's latest filing, from $529639.8 in the prior quarter.
• Across five years, Cost of Revenue topped out at $19.4 million in Q4 2023 and bottomed at -$577211.7 in Q2 2024.
• Historically, Cost of Revenue has averaged $6.4 million across 5 years, with a median of $4.2 million in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 7030.16% — and 2024, when it sank 112.54%.
• Lakefront Biotherapeutics' Cost of Revenue stood at $4.2 million in 2022, then soared by 358.41% to $19.4 million in 2023, then slumped by 90.62% to $1.8 million in 2024, then slumped by 70.84% to $529639.8 in 2025, then soared by 960.8% to $5.6 million in 2026.
• Business Quant data shows LKFT's Cost of Revenue at $5.6 million in Q1 2026, $529639.8 in Q4 2025, and $12.7 million in Q3 2025.